查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1338910

促红血球生成素製剂市场、份额、规模、趋势、产业分析报告:按产品、按类型、按应用、按地区、按细分市场、预测2023-2032

Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，到 2032 年，全球促红血球生成素市场预计将达到 76.5 亿美元。该报告提供了对当前市场动态的详细洞察，并对未来市场成长进行了分析。

贫血是世界主要的健康问题，而促红血球生成素製剂是主要的治疗方法。根据 CDC 的慢性肾臟病指南，估计美国 15% 的成年人（即 3,700 万人）患有 CKD。慢性肾臟病在老年人中比 45 至 64 岁 (13%) 和 18 至 44 岁 (7%) 更常见。此外，对替代品牌药物的廉价生物相似药的需求不断增加，预计将增加对促红血球生成素製剂的需求。

北美地区促红血球生成素製剂的采用率高于其他地区。这是由于多种因素造成的，包括贫血和慢性肾臟病的高盛行率、先进的医疗基础设施以及大型製药公司的存在。

此外，有利的政府政策和报销制度也促进了促红血球生成素产品在北美的广泛使用。例如，在美国，医疗保险涵盖末期肾病患者的促红血球生成素治疗，大大增加了患者获得促红血球生成素产品的机会。

你有任何问题吗？您想在购买此报告之前索取样品或进行询价吗？

2023 年2 月，GSK生产的JessDuBroke 片剂获得美国食品和药物管理局批准，成为首个口服治疗药物，用于治疗因慢性肾臟病而患有贫血并接受透析四个月或更长时间的成人。这项批准代表了慢性肾臟病引起的贫血治疗的重大突破，为以前不得不依赖注射促红血球生成素的患者提供了更简单、更容易获得的治疗选择。

2022年11月，英国国家医疗服务体系实现了突破，进行了世界上首次输注由供体细胞培养的红血球。这项科学里程碑可能为罕见血型患者的治疗开闢新途径。

促红血球生成素製剂市场报告亮点

生物製品领域主导市场并占收入的很大一部分。受欢迎的产品包括 Procrit、Neolecolmon、Epogin、Mircera、Aranesp 和 Epogen。

到2022年，促红血球生成素细分市场将占据最大的市场份额。依泊汀-BETA 在维持血液透析患者的血红素水平方面优于依泊汀-ALPHA，因此预计未来会出现正增长。

2022年，肾臟病细分市场将占据最大市场份额，肾臟移植及相关疾病报销政策的製定也正在推动该细分市场的发展。

北美在市场上占据主导地位，由于药物先驱的存在、CKD 患者的医疗保险覆盖以及 FDA 对 Epogen、Aranesp 和 Procrit Masu 等药物的批准，预计在预测期内将以最高的复合年增长率增长。

目录

第 1 章 简介

第二章执行摘要

第三章研究方法论

第四章全球促红血球生成素药物市场洞察

  • 促红血球生成素製剂市场 - 产品概况
  • 促红血球生成素製剂市场动态
    • 驱动因素和机遇
      • 慢性病发病率增加
      • 红血球生成刺激剂 (ESA) 的超说明书使用
    • 限制因素和挑战
      • 品牌涌入
  • PESTEL 分析
  • 促红血球生成素药物市场的产品趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章全球促红血球生成素製剂市场（按类型）

  • 主要发现
  • 介绍
  • 生物製剂
  • 生物相似药

第六章全球促红血球生成素药物市场（依应用）

  • 主要发现
  • 介绍
  • 癌症
  • 肾臟疾病
  • 神经病学
  • 其他

第七章全球促红血球生成素製剂市场，依产品

  • 主要发现
  • 介绍
  • 促红细胞生成素
  • 达贝泊汀阿尔法

第八章全球促红血球生成素製剂市场（按地区）

  • 主要发现
  • 介绍
    • 2019-2032年促红血球生成素製剂市场评估（按地区）
  • 促红血球生成素医药市场 - 北美
    • 北美:2019-2032 年促红血球生成素製剂市场（按类型）
    • 北美:促红血球生成素製剂市场（按产品），2019-2032
    • 北美:促红血球生成素製剂市场，依应用分类，2019-2032
    • 促红血球生成素製剂市场－美国
    • 促红血球生成素药品市场－加拿大
  • 促红血球生成素药物市场－欧洲
    • 欧洲:2019-2032 年促红血球生成素製剂市场（按类型）
    • 欧洲:促红血球生成素製剂市场（依产品），2019-2032
    • 欧洲:促红血球生成素製剂市场，依应用划分，2019-2032
    • 促红血球生成素药品市场－英国
    • 促红血球生成素製剂市场－法国
    • 促红血球生成素製剂市场－德国
    • 促红血球生成素製剂市场－义大利
    • 促红血球生成素製剂市场－西班牙
    • 促红血球生成素製剂市场－荷兰
    • 促红血球生成素製剂市场－俄罗斯
  • 促红血球生成素药物市场 - 亚太地区
    • 亚太地区:2019-2032 年促红血球生成素製剂市场（按类型）
    • 亚太地区:促红血球生成素製剂市场（依产品），2019-2032
    • 亚太地区:促红血球生成素製剂市场，依应用划分，2019-2032
    • 促红血球生成素医药市场 - 中国
    • 促红血球生成素药品市场－印度
    • 促红血球生成素药品市场 - 马来西亚
    • 促红血球生成素製剂市场－日本
    • 促红血球生成素药品市场—印尼
    • 促红血球生成素製剂市场－韩国
  • 促红血球生成素製剂市场－中东和非洲
    • 中东和非洲:2019-2032 年促红血球生成素製剂市场（按类型）
    • 中东和非洲:促红血球生成素製剂市场（按产品），2019-2032
    • 中东和非洲:促红血球生成素製剂市场，依应用划分，2019-2032
    • 促红血球生成素药品市场－沙乌地阿拉伯
    • 促红血球生成素製剂市场－阿拉伯联合大公国
    • 促红血球生成素製剂市场－以色列
    • 促红血球生成素药品市场－南非
  • 促红血球生成素製剂市场－拉丁美洲
    • 拉丁美洲:2019-2032 年促红血球生成素製剂市场（按类型）
    • 拉丁美洲:促红血球生成素製剂市场，分产品，2019-2032
    • 拉丁美洲:促红血球生成素製剂市场，依应用分类，2019-2032
    • 促红血球生成素药品市场—墨西哥
    • 促红血球生成素药品市场 - 巴西
    • 促红血球生成素製剂市场－阿根廷

第9章 竞争格局

  • 扩张和收购分析
    • 扩张
    • 获得
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • Amgen
  • Johnson & Johnson
  • Roche Ltd
  • Pfizer
  • Biocon
  • Teva Pharmaceutical
  • Kyowa Kirin
  • LG Life Sciences
  • AstraZeneca
  • Intas Pharmaceuticals
  • Shire
  • Sanofi
  • Novartis
  • Boehringer Ingelheim
  • Baxter International Inc.
Product Code: PM3354

The global erythropoietin drugs market size is expected to reach USD 7.65 billion by 2032, according to a new study by Polaris Market Research. The report "Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anemia is a major health concern globally, and Erythropoietin Drugs are the primary treatment for the condition. According to the CDC chronic kidney disease in the United States, 15% of adults in the USA, or 37 million people are estimated to have CKD. It is more common in old age population than in people aged 45-64 years (13%) and 18-44 years (7%). Moreover, the increasing demand for biosimilars, which are cheaper alternatives to branded drugs, is expected to drive the need for Erythropoietin Drugs.

Adoption of erythropoietin drugs is greater in North America compared to other regions. This is due to several factors such as the high prevalence of anemia and chronic kidney disease, the availability of advanced healthcare infrastructure, and the presence of a large number of major pharmaceutical companies in the region.

Additionally, favorable government policies and reimbursement schemes have also contributed to the widespread adoption of erythropoietin drugs in North America. For example, in the United States, Medicare provides coverage for erythropoietin therapy for patients with end-stage renal disease, which has significantly increased access to these drugs for patients in the country.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report?

In February 2023, Jesduvroq tablets, manufactured by GSK, received approval from the U.S. Food and Drug Administration as the first oral treatment option for adults suffering from anaemia due to chronic kidney disease and who have undergone dialysis for at least four months. This approval represents a significant breakthrough in the treatment of anaemia caused by chronic kidney disease, as it offers a more convenient and easily accessible treatment option for patients who previously had to rely on injectable erythropoietin drugs.

In November 2022, the UK's National Health Service made a ground-breaking achievement by performing the first-ever transfusion of lab-grown RBCs grown from the donor cells. This scientific milestone could open up new avenues for treating people with the rare blood types.

Erythropoietin Drugs Market Report Highlights

The biologics segment dominates the market, accounting for a significant share of revenue, with popular products including Procrit, NeoRecormon, Epogin, Mircera, Aranesp, and Epogen.

The erythropoietin segment holds the largest market share in 2022. Epoetin-beta is expected to grow positively in the future due to its superiority in maintaining hemoglobin concentration in hemodialysis patients over Epoetin-alfa.

The renal diseases segment holds the largest share of the market In 2022, due to developed reimbursement policies for renal transplants and related diseases are also driving this segment.

North America dominated the market and is expected to grow at a highest CAGR over the projected period because of the presence of organizations advancing drug development, Medicare coverage for CKD patients, and FDA approval of drugs like Epogen, Aranesp, and Procrit.

The global players include: Amgen, Johnson & Johnson, Roche, Pfizer, Biocon, and Teva Pharmaceutical.

Polaris Market Research has segmented the Erythropoietin Drugs market report based on type, product, application and region:

Erythropoietin Drugs, Type Outlook (Revenue, USD Billion, 2019 - 2032)

  • Biologics
  • Biosimilars

Erythropoietin Drugs, Product Outlook (Revenue, USD Billion, 2019 - 2032)

  • Erythropoietin
  • Darbepoetin-alfa

Erythropoietin Drugs, Application Outlook (Revenue, USD Billion, 2019 - 2032)

  • Cancer
  • Renal Diseases
  • Neurology
  • Others

Erythropoietin Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Erythropoietin Drugs Market Insights

  • 4.1. Erythropoietin Drugs Market - Product Snapshot
  • 4.2. Erythropoietin Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of chronic diseases
      • 4.2.1.2. Off-label use of Erythropoiesis stimulating agents (ESAs)
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Patent expiration of branded drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Erythropoietin Drugs Market Product Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Erythropoietin Drugs Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Biologics
    • 5.3.1. Global Erythropoietin Drugs Market, by Biologics, by Region, 2019-2032 (USD Billion)
  • 5.4. Biosimilars
    • 5.4.1. Global Erythropoietin Drugs Market, by Biosimilars, by Region, 2019-2032 (USD Billion)

6. Global Erythropoietin Drugs Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Cancer
    • 6.3.1. Global Erythropoietin Drugs Market, by Cancer, by Region, 2019-2032 (USD Billion)
  • 6.4. Renal Diseases
    • 6.4.1. Global Erythropoietin Drugs Market, by Renal Diseases, by Region, 2019-2032 (USD Billion)
  • 6.5. Neurology
    • 6.5.1. Global Erythropoietin Drugs Market, by Neurology, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Erythropoietin Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Erythropoietin Drugs Market, by Product

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • 7.3. Erythropoietin
    • 7.3.1. Global Erythropoietin Drugs Market, by Erythropoietin, By Region, 2019-2032 (USD Billion)
  • 7.4. Darbepoetin-alfa
    • 7.4.1. Global Erythropoietin Drugs Market, by Darbepoetin-alfa, By Region, 2019-2032 (USD Billion)

8. Global Erythropoietin Drugs Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Erythropoietin Drugs Market - North America
    • 8.3.1. North America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.3.3. North America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Erythropoietin Drugs Market - U.S.
      • 8.3.4.1. U.S.: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Erythropoietin Drugs Market - Canada
      • 8.3.5.1. Canada: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Erythropoietin Drugs Market - Europe
    • 8.4.1. Europe: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Erythropoietin Drugs Market - UK
      • 8.4.4.1. UK: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Erythropoietin Drugs Market - France
      • 8.4.5.1. France: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Erythropoietin Drugs Market - Germany
      • 8.4.6.1. Germany: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Erythropoietin Drugs Market - Italy
      • 8.4.7.1. Italy: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Erythropoietin Drugs Market - Spain
      • 8.4.8.1. Spain: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Erythropoietin Drugs Market - Netherlands
      • 8.4.9.1. Netherlands: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Erythropoietin Drugs Market - Russia
      • 8.4.10.1. Russia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Erythropoietin Drugs Market - Asia Pacific
    • 8.5.1. Asia Pacific: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Erythropoietin Drugs Market - China
      • 8.5.4.1. China: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Erythropoietin Drugs Market - India
      • 8.5.5.1. India: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Erythropoietin Drugs Market - Malaysia
      • 8.5.6.1. Malaysia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Erythropoietin Drugs Market - Japan
      • 8.5.7.1. Japan: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Erythropoietin Drugs Market - Indonesia
      • 8.5.8.1. Indonesia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Erythropoietin Drugs Market - South Korea
      • 8.5.9.1. South Korea: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Erythropoietin Drugs Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Erythropoietin Drugs Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Erythropoietin Drugs Market - UAE
      • 8.6.5.1. UAE: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Erythropoietin Drugs Market - Israel
      • 8.6.6.1. Israel: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Erythropoietin Drugs Market - South Africa
      • 8.6.7.1. South Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Erythropoietin Drugs Market - Latin America
    • 8.7.1. Latin America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Erythropoietin Drugs Market - Mexico
      • 8.7.4.1. Mexico: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Erythropoietin Drugs Market - Brazil
      • 8.7.5.1. Brazil: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Erythropoietin Drugs Market - Argentina
      • 8.7.6.1. Argentina: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Amgen
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Johnson & Johnson
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Roche Ltd
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Pfizer
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Biocon
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Teva Pharmaceutical
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Kyowa Kirin
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. LG Life Sciences
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. AstraZeneca
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Intas Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Shire
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Sanofi
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Novartis
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Boehringer Ingelheim
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. Baxter International Inc.
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development

List of Tables

  • Table 1 Global Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 4 Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 8 U.S.: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 11 Canada: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 14 Europe: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 17 UK: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 20 France: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 23 Germany: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Italy: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 29 Spain: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 35 Russia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 41 China: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 44 India: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Japan: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 56 South Korea: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 65 UAE: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 68 Israel: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 71 South Africa: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 74 Latin America: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 77 Mexico: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 80 Brazil: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)
  • Table 83 Argentina: Erythropoietin Drugs Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Erythropoietin Drugs Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Erythropoietin Drugs Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Erythropoietin Drugs Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Erythropoietin Drugs Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Erythropoietin Drugs Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Product
  • Figure 11. Global Erythropoietin Drugs Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 12. Erythropoietin Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Erythropoietin Drugs Market